• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by NewGenIvf Group Limited

    9/4/24 7:30:26 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care
    Get the next $NIVF alert in real time by email
    6-K 1 ea0213191-6k_newgen.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

      

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER
    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
    THE SECURITIES EXCHANGE ACT OF 1934

      

    For the month of September 2024

      

    Commission File Number: 001-42004

      

    NEWGENIVF GROUP LIMITED
    (Translation of registrant’s name into English)

      

    36/39-36/40, 13th Floor, PS Tower

    Sukhumvit 21 Road (Asoke) 

    Khlong Toei Nuea Sub-district 

    Watthana District, Bangkok 10110 

    Thailand

    (Address of Principal executive offices)

      

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒     Form 40-F ☐

     

     

     

     

     

     

    Effective on September 3, 2024, Newgenivf Group Limited (the “Registrant”) has appointed J&S Associate (“J&S”) as its independent registered public accounting firm for the fiscal year ending December 31, 2024. The Registrant has terminated the services of the Registrant’s previous independent auditor, Onestop Assurance PAC (“Onestop”) effective on September 3, 2024. The termination of Onestop and the appointment of J&S was made after careful consideration and evaluation by the Registrant and has been approved by the Audit Committee and the Board of Directors of the Registrant.

      

    During the Registrant’s two most recent fiscal years ended December 31, 2023 and 2022, through the termination of services of Onestop on September 3, 2024, there were no disagreements between the Registrant and Onestop on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Onestop, would have caused it to make reference to the subject matter of the disagreements in connection with its report on the Registrant’s consolidated financial statements for such periods. In addition, Onestop’s reports on the financial statements as of and for the fiscal year ended December 31, 2023 did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles. During the fiscal year ended December 31, 2023 through the termination of services of Onestop on September 3, 2024, there were no “reportable events” as that term is defined in Item 16F(a)(1)(v) of Form 20-F.

      

    During the two most recent fiscal years ended December 31, 2023 and 2022 and the subsequent interim period prior to engaging J&S, neither the Registrant nor anyone on its behalf consulted J&S regarding either (i) the application of accounting principles to any proposed or completed transaction, or the type of audit opinion that might be rendered on the Registrant’s financial statements, and neither a written report nor oral advice was provided to the Registrant that J&S concluded was an important factor considered by the Registrant in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 16F(a)(1)(iv) of Form 20-F and the related instructions to Item 16F of Form 20-F) or a reportable event.

      

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: September 4, 2024

     

      NewGenIvf Group Limited
         
      By: /s/ Wing Fung Alfred Siu
      Name:  Wing Fung Alfred Siu
      Title: Chairman of the Board and Director

     

     

    2

     

    Get the next $NIVF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NIVF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NIVF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Chardan Capital Markets Llc claimed ownership of 1,569,000 units of Class A Ordinary Shares (SEC Form 3)

    3 - NewGenIvf Group Ltd (0001981662) (Issuer)

    11/13/24 9:16:27 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    SEC Filings

    View All

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    1/20/26 8:07:33 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    12/2/25 8:01:34 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    11/25/25 4:00:29 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NewGen and Evident Capital Successfully Activate Commitment Campaign for Inaugural Tokenized Real Estate Bond, Delivering on Cross-Border Real World Asset Financing Strategy

    Rapid progress from announcement of successful launch in under two weeks signals NewGen's expertise and commitment Launch represents fulfilment of NewGen's goals to spearhead Real World Asset tokenization, puts Company at the forefront of digital assets innovation BANGKOK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a tech-forward, diversified, multi-jurisdictional entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, is pleased to announce that the Commitment Campaign for its inaugural tokenized bond issuance is now live on Evident Ca

    2/4/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGen to Execute Up to US$2 Million Share Repurchase Program Through Benchmark

    BANGKOK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a tech-forward, diversified, multi-jurisdictional entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced that it intends to execute its previously authorized share repurchase program initially announced on November 10, 2025 through The Benchmark Company, LLC ("Benchmark"), a subsidiary of StoneX Group Inc. ("StoneX"). Management believes that NewGen's current market valuation does not fully reflect the Company's underlying business fundamentals, ongoing initiatives, and

    1/27/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NIVF Appoints Award-Winning Web3 Leader Joshua Chu to Spearhead Tokenization Strategy and Formally Engages Evident Capital to Launch Up to USD 30 Million in Tokenized Bonds by Q1, Outlining 2026 Value Catalysts

    BANGKOK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (("NewGen" or the "Company, NASDAQ:NIVF), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and real estate development, today announced the appointment of award-winning Web3 legal and regulatory specialist Joshua Chu as Senior Counsel to lead the Group's tokenization strategy, alongside the formal engagement of Evident Capital, Hong Kong's first fully integrated, SFC-licensed tokenization and alternative assets platform, to support the launch of NIVF's inaugural tokenized bond issuance of up to USD 30 million targeted for completion by the first quarter of 2026. As S

    1/21/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Leadership Updates

    Live Leadership Updates

    View All

    NIVF Appoints Award-Winning Web3 Leader Joshua Chu to Spearhead Tokenization Strategy and Formally Engages Evident Capital to Launch Up to USD 30 Million in Tokenized Bonds by Q1, Outlining 2026 Value Catalysts

    BANGKOK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (("NewGen" or the "Company, NASDAQ:NIVF), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and real estate development, today announced the appointment of award-winning Web3 legal and regulatory specialist Joshua Chu as Senior Counsel to lead the Group's tokenization strategy, alongside the formal engagement of Evident Capital, Hong Kong's first fully integrated, SFC-licensed tokenization and alternative assets platform, to support the launch of NIVF's inaugural tokenized bond issuance of up to USD 30 million targeted for completion by the first quarter of 2026. As S

    1/21/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGenDigital Appointed as SAXA Inc.'s Agent for Tokenization of US$100 Million of Gold-backed Assets

    Service agreement with SAXA, Inc. appoints NewGenDigital as SAXA's worldwide tokenization agent, strengthening cooperation between the two companies ahead of proposed reverse merger Value of tokenized assets could be expanded to US$1 billion under the terms of the agreement; NewGenDigital to earn 5% commission on assets sold BANGKOK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced that its subsidiary, NewGenD

    11/5/25 9:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director

    Company Granted Request to Continue its Listing on NasdaqAppoints Thorain Ko to Lead Business Development Initiatives BANGKOK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Stock Market, subject to specific conditions. Additionally, the Company announced the appointment of Mr. Thorain Ko as Business Development Director to drive its expansion initiatives. Nasdaq Listing UpdateThe Pane

    2/20/25 6:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    12/5/24 8:23:57 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    11/13/24 9:19:27 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    10/10/24 3:39:26 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care